Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025. At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners acro
Biotechnology, Pharmaceuticals, Health
2025-10-06 3:15 AM EDT | Defence Therapeutics Inc.
Canadian-made Stable Isotopes: TMC Group Attends EANM 2025 to Strengthen Global Supply Chains
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - TMC Group, a manufacturer of high-purity stable isotopes, is attending the European Association of Nuclear Medicine (EANM) 2025 Annual Congress, October 4-8 in Barcelona. TMC Group's enriched stable isotopes have been supporting groundbreaking scientific research and innovation around the world since 2004. "We've been quietly providing a safe, reliable supply of enriched stable isotopes to world-leading researchers and li
Technology, Biotechnology, Chemical, Pharmaceuticals
2025-10-02 10:00 AM EDT | TMC Group
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building
Biotechnology, Pharmaceuticals, Health
2025-10-02 3:15 AM EDT | Defence Therapeutics Inc.
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic
Biotechnology, Pharmaceuticals
2025-10-01 8:30 AM EDT | Entero Therapeutics, Inc.
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it has entered into a definitive Asset Purchase Agreement (the "Agreement") for the sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a well-established global pharmaceutical co
Biotechnology, Pharmaceuticals
2025-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.
Telescope Innovations Produces Battery-Grade Lithium Carbonate from Recycled Waste Streams
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") is a leader in intelligent automation platforms for accelerating chemical process development. The Company today announced a key milestone in its lithium refinement technology pipeline: successful isolation of lithium from a battery recycling waste stream. The captured lithium was converted int
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-09-29 8:00 AM EDT | Telescope Innovations Corp.
CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center
Houston, Texas--(Newsfile Corp. - September 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) announces a Statewide Educational Seminar Series on the TCUP Expansion, as Texas healthcare is experiencing a historic breakthrough with the approval of House Bill 46 (HB 46). Signed into law on June 21, 2025, by Governor Greg Abbott, the expansion of the Texas Compassionate Use Program (TCUP) will cover chronic pain, PTSD, and degenerative neurological conditions, among othe
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-09-29 7:00 AM EDT | Cannabis Bioscience International Holdings
Quantum BioPharma Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-26 8:00 PM EDT | Quantum BioPharma Ltd.
NuGen Medical Devices Announces NHS Drug Tariff Approval for EziAutoJector(R) Product Line in the UK
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is pleased to announce that its exclusive UK distribution partner, EziAutoJector® Ltd, has received confirmation from the NHS Business Services Authority, on behalf of the Department of Health, that EziAutoJector® products have been approved for inclusion in the NHS Drug Tariff.
Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-26 5:30 PM EDT | NuGen Medical Devices Inc.
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors. Detailed voting results for the ele
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-25 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Unbuzzd Wellness Raising Up To $5 Million USD Through Reg D 506 (c) Offering; Hosting Live Webinar and Q&A for Interested Accredited Investors on Wednesday, October 1, 2025 at 4:30 PM EST (1:30 PM PST)
Vancouver, British Columbia--(Newsfile Corp. - September 25, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM ("unbuzzd") — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms — today announced that, as part of its Reg D 506 (c) offering and up to $5 million raise, the Company will host an Investor Webinar o
2025-09-25 7:00 AM EDT | Unbuzzd Wellness Inc.
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus
Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, announced today the peer-reviewed publication of independent preclinical data demonstrating the superiority of its lead antiviral cand
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-09-24 7:00 AM EDT | Theralase Technologies Inc.
Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to ann
Biotechnology, Pharmaceuticals, Health
2025-09-23 12:22 PM EDT | Hemostemix Inc.
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17t
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-23 12:16 PM EDT | Neural Therapeutics Inc.
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.
Biotechnology, Pharmaceuticals, Health
2025-09-23 9:15 AM EDT | Defence Therapeutics Inc.
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025
Biotechnology, Pharmaceuticals
2025-09-23 8:30 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-23 7:45 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction
Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.
Biotechnology, Pharmaceuticals, Health
2025-09-22 6:32 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual ge
Biotechnology, Pharmaceuticals, Health
2025-09-19 6:00 PM EDT | PreveCeutical Medical Inc.